Skip to content
    Clinical Trials

    Semaglutide for Obesity in Children Aged 6 to <12 Years: STEP Young Trial Results

    Jastreboff et alThe New England journal of medicine

    Semaglutide for Obesity in Children Aged 6 to <12 Years: STEP Young Trial Results
    Childhood obesity is a chronic, neurometabolic condition with limited durable medical treatment options. While subcutaneous semaglutide is approved for adolescents and adults, data on younger pediatric populations have been lacking. The phase 3, double-blind, randomized, placebo-controlled STEP Young trial evaluated the efficacy and safety of once-weekly subcutaneous semaglutide combined with lifestyle modification in children aged 6 to <12 years.
    A total of 167 children were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (n = 112) or placebo (n = 55) for 104 weeks, followed by a 7-week washout period. The primary endpoint was the percent change in body-mass index (BMI) from baseline to week 68, and the confirmatory secondary endpoint was a reduction in BMI category at week 68.
    At week 68, treatment with semaglutide resulted in a significantly greater mean percent reduction in BMI compared to placebo (-13.5% vs 2.7%; estimated between-group difference, -16.2 percentage points; 95% CI, -19.4 to -12.9; P<0.001). At week 104, the mean percent change in BMI was -9.4% with semaglutide versus 8.4% with placebo (estimated between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). Furthermore, 79% of participants in the semaglutide group achieved a reduction in BMI category at week 68 compared to 23% in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with 38% of semaglutide-treated children falling below the 95th percentile threshold for obesity versus 2% in the placebo cohort.
    Adverse events were reported in 96% of the semaglutide group and 93% of the placebo group. Gastrointestinal symptoms were the most common adverse events, occurring more frequently in the semaglutide group and leading to treatment discontinuation in 1 participant. The trial was funded by Novo Nordisk (ClinicalTrials.gov number, NCT05726227).

    Key Takeaways

    • At week 68, once-weekly semaglutide achieved a mean BMI reduction of -13.5% compared with an increase of 2.7% for placebo (estimated difference, -16.2 percentage points; 95% CI, -19.4 to -12.9; P<0.001), maintaining a -17.8 percentage-point difference at week 104 (-9.4% vs 8.4%; 95% CI, -22.2 to -13.3).
    • A reduction in BMI category was reached by 79% of children receiving semaglutide compared with 23% receiving placebo (OR 7.8; 95% CI, 3.5 to 17.6; P<0.001), with 38% versus 2% reducing their BMI below the 95th percentile obesity threshold.
    • Adverse events were reported in 96% of participants receiving semaglutide and 93% receiving placebo, with gastrointestinal symptoms being the most frequent and leading to treatment discontinuation in 1 child in the semaglutide group.
    Read the original sourceThe New England journal of medicine